ArticleJournal of thoracic disease2025
PSMD11 facilitates immune escape by recruiting USP14 to modulate the deubiquitinating degradation of PD-L1 in non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The PSMD11 has been shown to be associated with the malignant progression and clinical outcomes of various carcinomas. However, the molecular mechanism of PSMD11 in non-small cell lung cancer (NSCLC) remains unknown. In this study, we investigated the molecular mechanism of PSMD11 effect on the immune escape in NSCLC. Methods: Co-culture models of NSCLC cells and T cells were constructed. Colony formation assays and flow cytometry were used to detect the proliferation and apoptosis of NSCLC cells in the co-culture system after the knock down of PSMD11. Western blotting was used to detect the expression of programmed death-ligand 1 (PD-L1) after the knock down of PSMD11. Co-immunoprecipitation (co-IP) assays were used to observe the interaction between PD-L1 and PSMD11 and USP14 in the A549 and H1299 cells. The in vivo effects of PSMD11 were analyzed using a xenograft tumor model. Results: In the NSCLC cell/T cell co-culture models, the knockdown of PSMD11 significantly upregulated T cell-mediated apoptosis and enhanced the killing effect of T cells in the A549 and H1299 cells, and also significantly upregulated the expression of killer T cell markers Granzyme and perforin in the T cells. We also found that the knockdown of PSMD11 inhibited the expression of PD-L1. The mass spectrometry (MS) and co-IP results showed that PSMD11 interacted with PD-L1 and the deubiquitinating enzyme USP14. Overexpression of USP14 leads to an increase in the protein level of PD-L1, while knocking down PSMD11 can reverse this elevated state. The overexpression of PD-L1 and USP14 in the NSCLC cells reversed the effects of PSM11 on immune escape. Conclusions: This study showed that PSMD11 recruits USP14 to modulate the deubiquitinating degradation of PD-L1 to promote immune escape in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.